Ganoderma lucidum polysaccharide inhibits LPS-induced inflammatory injury to mammary epithelial cells
Yi Fan, Wei Wang, Xuefang Wang, Liqin Yu, Yue Wei, Lei Wei, Xiaoyang Xie, Xiao Li
Abstract
This study sought to investigate whether Ganoderma lucidum polysaccharide (GLP) has a protective effect on lipopolysaccharide (LPS)-induced inflammatory injury to mammary epithelial HC-11 cells and to characterize the mechanism involved. Cell viability was assessed using the cell counting kit 8 (CCK-8) method, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-1β levels were measured by enzyme linked immunosorbent assay (ELISA), and IκBa, p65 NF-κB and STAT3 mRNA were determined using quantitative reverse transcription PCR (qRT-PCR), p65 and STAT3 protein expression were determined using Western blotting, respectively. GLP was shown to inhibit LPS-induced TNF-α, IL-6, and IL-1β production (P < 0.01 or P < 0.05), GLP was also shown to increase IκBα mRNA expression (P < 0.01), decrease p65 and STAT3 mRNA expression (P < 0.01 or P < 0.05), and decrease p-p65, p65, p-STAT3, and STAT3 protein expression in breast epithelial cells (P < 0.01 or P < 0.05). The findings suggest that GLP inhibits nuclear factor kappa-B (NF-κB) and signal transducers and activators of transcription (STAT) signaling by preventing IκBα degradation and p65 and STAT3 phosphorylation. This results in lower LPS-induced TNF-α, IL-6, and IL-1β production and prevents inflammatory cell injury.